DiaMedica director granted options for 40,412 shares

DiaMedica Therapeutics Inc. director Daniel J. O'Connor received a grant of stock options to acquire 40,412 voting common shares.

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director Daniel J. O'Connor received a grant of stock options to acquire 40,412 voting common shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments. Following this grant, he holds options for 40,412 shares directly.

Insider Trade Summary

Grant/Award: 40,412 shares

Grant/Award 1 txn

Insider O'Connor Daniel J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,412	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 40,412 contracts (Direct)

Footnotes (1)

1. F1. Scheduled to vest in four equal quarterly installments.

Key Figures

Options granted: 40,412 shares Exercise price: $5.84 per share Total options after grant: 40,412 shares +3 more

6 metrics

Options granted 40,412 shares Stock Option (right to buy) granted to director

Exercise price $5.84 per share Conversion or exercise price of stock options

Total options after grant 40,412 shares Total derivative shares following transaction

Expiration date June 1, 2036 Option expiration for granted stock options

Transaction date June 1, 2026 Date of stock option grant

Vesting schedule Four equal quarterly installments Footnote on option vesting terms

Key Terms

Stock Option (right to buy), grant/award acquisition, exercise price, expiration date, +2 more

6 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 5.8400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

voting common shares financial

"underlying_security_title: Voting Common Shares"

derivative securities financial

"transaction_type: derivative"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DiaMedica Therapeutics (DMAC) report for Daniel J. O'Connor?

DiaMedica Therapeutics reported that director Daniel J. O'Connor received a grant of stock options for 40,412 voting common shares. These options were awarded as a compensation-related acquisition, not an open-market share purchase or sale.

What are the key terms of Daniel J. O'Connor's new DiaMedica (DMAC) stock options?

The stock options cover 40,412 voting common shares at an exercise price of $5.84 per share. They expire on June 1, 2036 and were granted directly to O'Connor as a compensation-related award.

How do Daniel J. O'Connor's DiaMedica (DMAC) options vest after this Form 4 filing?

The options granted to Daniel J. O'Connor are scheduled to vest in four equal quarterly installments. This means the 40,412 underlying shares become exercisable in stages over four quarters, rather than all at once on the grant date.

Is the DiaMedica (DMAC) Form 4 for Daniel J. O'Connor a stock purchase or sale?

The Form 4 reflects a grant or award acquisition of derivative securities, not a market trade. O'Connor received stock options with rights to buy 40,412 shares; there were no reported open-market purchases or sales in this filing.

How many DiaMedica (DMAC) options does Daniel J. O'Connor hold after this transaction?

After the reported grant, Daniel J. O'Connor holds stock options covering 40,412 voting common shares. This total reflects his direct derivative position as of the transaction date disclosed in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 05:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor Daniel J.

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		40,412		(1)	06/01/2036	Voting Common Shares	40,412	$0	40,412	D

Explanation of Responses:

1. Scheduled to vest in four equal quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)